Ratings HAEMATO AG Xetra

Equities

Delayed Xetra Other stock markets 11:36:27 2024-02-29 am EST			5-day change	1st Jan Change
21.4 ^EUR	-1.83%		-.--%	-23.02%

The company shows low valuation levels, with an enterprise value at 0.24 times its sales.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company does not generate enough profits, which is an alarming weak point.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HAEMATO AG	-23.02%	93.87M		-
KYOWA KIRIN CO. LTD.	+34.09%	10.31B		A-
YUHAN CORPORATION	+40.84%	5.23B		B-
SK BIOPHARMACEUTICALS CO., LTD.	-18.53%	4.62B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+12.65%	3.52B		-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+27.58%	2.31B	-	-
BETTA PHARMACEUTICALS CO., LTD.	-39.96%	1.78B		C-
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-45.87%	1.69B		-
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B	-	-
SUPERNUS PHARMACEUTICALS, INC.	0.00%	1.59B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality